The spellchecking one was gold.

First 549 Last

Share
Profile

Follow
knowwhat

1,684 Posts.

248

25/06/24

07:54

Post #: 74470655
Share

Originally posted by Abdubul: ↑

To be fair - all a new investor would have to do would be to compare every single 4C to the overly optimistic predictions consistently peddled by management to be deterred from further engagement. The company does not have a clear strategic plan, it just lurches from idea to idea, each one more poorly executed than the next.

This was a SaaS company that was going to revolutionise invoicing. Then it was going to provide millions of dollars worth of factoring to agribusiness. Then it was going to be the saviour of food security via blockchain. Next it was in the on line farm equipment auction business. I think the latest idea is to run EFTPOS terminals. No one really knows because no one seems to be able to explain what this company does. Certainly not the CEO. They haven’t made the building tall enough to give us time to hear his elevator pitch.

What gets said here is of no consequence in comparison.

Regardless, it won’t take much investigation of these threads to see that the bears here talk data, facts, numbers and financials while the bulls talk speculatively about partnerships and deals and situations that never seem to come to fruition.

Some of the more entertaining ones over the journey:

”We’ll be cashflow positive next quarter” (said every quarter)

”Revenue is profit obviously”

”We’re growing at a record rate” (while posting record losses)

”There’s a big announcement coming, it’s just being spellchecked”. Still waiting for that announcement by the way.

SPX has also been compared favourably to Mastercard, GrainCorp, CBA, BHP, Google and Apple by the blind optimists here.

All of this is very telling. New investors will make up their own minds. If you’ve stuck it out this far I certainly don't blame you for continuing to hold. Good luck!

Expand

The spellchecking one was gold.

SPX Price at posting: 0.7¢ Sentiment: None Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

SPR

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

MSB

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

SRL

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

PL3

Patagonia looks to raise $2.15M for South American exploration and development

OCC

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

There are more pages in this discussion • 313 more messages in this thread...

First 549 Last

Add SPX (ASX) to my watchlist

(20min delay)
Last 0.8¢		Change 0.000(0.00%)		Mkt cap ! $34.59M

Open	High	Low	Value	Volume
0.8¢	0.8¢	0.7¢	$5.233K	659.1K

Buyers (Bids)

No.	Vol.	Price($)
10	7627966	0.7¢

Sellers (Offers)

Price($)	Vol.	No.
0.8¢	4085417	12

View Market Depth

No.	Vol.	Price($)
10	7627966	0.007
17	11135609	0.006
17	11370000	0.005
7	19000000	0.004
3	850001	0.003

Price($)	Vol.	No.
0.008	4085417	12
0.009	3040487	6
0.010	8626049	15
0.011	4983514	5
0.012	3671718	6

Last trade - 16.10pm 09/07/2024 (20 minute delay)

SPX (ASX) Chart

The spellchecking one was gold.

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Patagonia looks to raise $2.15M for South American exploration and development

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

The spellchecking one was gold.

Top Stories

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Patagonia looks to raise $2.15M for South American exploration and development

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News